8-K: Protalix BioTherapeutics Announces Second Quarter 2024 Financial Results and Business Update

Protalix BioTherapeutics reported a decrease in revenue and a net loss for the second quarter of 2024, while also highlighting progress in its clinical pipeline.

Summary

• Protalix BioTherapeutics reported its financial results for the second quarter of 2024, showing a decrease in revenue from selling goods to $13.3 million, a 12% decrease compared to $15.1 million in the same period last year.
• The company's revenue from license and R&D services significantly decreased by 99% to $0.2 million, down from $20.0 million in the second quarter of 2023, due to a large milestone payment from Chiesi in the prior year.
• Cost of goods sold increased by 56% to $9.5 million, primarily due to increased sales to Pfizer and Brazil.
• Research and development expenses decreased by 33% to $3.0 million, mainly due to the completion of the Fabry clinical program.
• The company reported a net loss of $2.2 million, or $0.03 per share, compared to a net income of $19.3 million, or $0.29 per share, in the same quarter of 2023.
• Cash, cash equivalents, and short-term bank deposits totaled approximately $45.0 million as of June 30, 2024.
• The company made progress in its pipeline, with positive results from the first seven cohorts of the Phase I clinical trial of PRX-115 for uncontrolled gout and plans to initiate a Phase II trial.
• The company collected approximately $4.6 million from sales to Pfizer and $2.3 million from sales to Brazil after the end of the quarter.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to the reported net loss and revenue decline, but there are positive aspects such as progress in the clinical pipeline and a strong balance sheet. The company is in a transitional phase with a focus on future growth.

Positives

• The company has a strong balance sheet enabling repayment of convertible notes due in September 2024.
• Positive topline results were achieved in the Phase I clinical trial of PRX-115 for uncontrolled gout.
• The company is preparing to initiate a Phase II clinical trial for PRX-115.
• Sales to Brazil and Pfizer increased, partially offsetting a decrease in sales to Chiesi.
• The company has $45 million in cash, cash equivalents and short term deposits.

Negatives

• Total revenue decreased significantly due to a large drop in license and R&D service revenue.
• The company reported a net loss of $2.2 million for the quarter.
• Cost of goods sold increased by 56% compared to the same period last year.
• Sales to Chiesi decreased by $10 million compared to the same period last year.

Risks

• The company faces risks related to the commercialization of Elfabrio, including market acceptance, competition, and regulatory actions.
• The ongoing conflict in Israel could disrupt operations, including those of regulatory authorities, suppliers, and partners.
• There are risks associated with the regulatory approval and commercial success of other product candidates.
• Global conditions such as supply chain challenges, inflation, and instability in the banking industry could adversely impact the business.
• The company faces risks related to raising additional capital and managing relationships with collaborators.
• There is a risk that clinical trial results may not support safety or efficacy claims.
• The company is dependent on third-party providers and faces potential product liability risks.

Future Outlook

The company anticipates topline results from all eight cohorts of the Phase I clinical trial of PRX-115 in the third quarter of 2024 and plans to initiate a Phase II clinical trial. The company also expects to repay its convertible notes due in September 2024.

Management Comments

• Dror Bashan, Protalix's President and Chief Executive Officer, stated that the company has made meaningful progress on its early-stage pipeline.
• Dror Bashan noted that results from the first seven cohorts of the phase I clinical trial of PRX-115 for the treatment of uncontrolled gout are encouraging.

Industry Context

The biopharmaceutical industry is characterized by high research and development costs and regulatory hurdles. Protalix's focus on plant cell-based protein expression is a unique approach, and the company's progress in clinical trials is a key factor for its future success. The company's partnerships with Pfizer and Chiesi are also important for commercialization.

Comparison to Industry Standards

• Protalix's revenue decline is significant compared to the previous year, primarily due to the absence of a large milestone payment, which is not uncommon in the biotech industry where revenue can be lumpy.
• The decrease in R&D expenses is expected as the company completes its Fabry clinical program, which is a typical lifecycle event for a biotech company.
• The increase in cost of goods sold is a result of increased sales to Pfizer and Brazil, which is a positive sign of commercial traction.
• The net loss is a concern, but it is not unusual for biotech companies in the development phase, especially when they are investing in clinical trials.
• Companies like Amgen and Regeneron, which are more established, have more stable revenue streams and higher R&D spending, but they also have a larger portfolio of products.
• Protalix's focus on plant-based protein production is a differentiator, but it also carries its own set of risks and challenges compared to traditional methods.

Stakeholder Impact

• Shareholders may be concerned about the net loss and revenue decline.
• Employees may be impacted by the company's financial performance and strategic decisions.
• Customers and partners may be interested in the progress of the company's clinical pipeline and commercialization efforts.
• Creditors may be interested in the company's ability to repay its debts.

Next Steps

• The company will release topline results from all eight cohorts of the Phase I clinical trial of PRX-115 in the third quarter of 2024.
• The company plans to initiate a Phase II clinical trial of PRX-115.
• The company will repay its convertible notes due in September 2024.

Key Dates

Keywords

Protalix BioTherapeutics, PRX-115, Elfabrio, Gout, Fabry disease, Clinical trial, Financial results, Biopharmaceutical, Recombinant protein, Plant cell-based expression system